Top

Published in:

01-04-2011 | Review

Clinical review: Adiponectin biology and its role in inflammation and critical illness

Authors: Katherine Robinson, John Prins, Bala Venkatesh

Published in: Critical Care | Issue 2/2011

Abstract

Adiponectin is an adipokine first described just over a decade ago. Produced almost exclusively by adipocytes, adiponectin circulates in high concentrations in human plasma. Research into this hormone has revealed it to have insulin-sensitizing, anti-inflammatory and cardioprotective roles. This review discusses the history, biology and physiological role of adiponectin and explores its role in disease, with specific focus on adiponectin in inflammation and sepsis. It appears that an inverse relationship exists between adiponectin and inflammatory cytokines. Low levels of adiponectin have been found in critically ill patients, although data are limited in human subjects at this stage. The role of adiponectin in systemic inflammation and critical illness is not well defined. Early data suggest that plasma levels of adiponectin are decreased in critical illness. Whether this is a result of the disease process itself or whether patients with lower levels of this hormone are more susceptible to developing a critical illness is not known. This observation of lower adiponectin levels then raises the possibility of therapeutic options to increase circulating adiponectin levels. The various options for modulation of serum adiponectin (recombinant adiponectin, thiazolidinediones) are discussed.

Available only for authorised users

Galic S, Oakhill JS, Steinberg GR: Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010, 316: 129-139. 10.1016/j.mce.2009.08.018CrossRefPubMed

Maury E, Brichard SM: Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010, 314: 1-16. 10.1016/j.mce.2009.07.031CrossRefPubMed

Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995, 270: 26746-26749. 10.1074/jbc.270.45.26746CrossRefPubMed

Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257: 79-83. 10.1006/bbrc.1999.0255CrossRefPubMed

Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB: Adiponectin - a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006, 8: 264-280. 10.1111/j.1463-1326.2005.00510.xCrossRefPubMed

Takahashi M, Arita Y, Yamagata K, Matsukawa Y, Okutomi K, Horie M, Shimomura I, Hotta K, Kuriyama H, Kihara S, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Genomic structure and mutations in adiposespecific gene, adiponectin. Int J Obes Relat Metab Disord 2000, 24: 861-868. 10.1038/sj.ijo.0801244CrossRefPubMed

Combs TP, Berg AH, Rajala MW, Klebanov S, Iyengar P, Jimenez-Chillaron JC, Patti ME, Klein SL, Weinstein RS, Scherer PE: Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes 2003, 52: 268-276. 10.2337/diabetes.52.2.268CrossRefPubMed

Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y: Androgens decrease plasma adiponectin, an insulinsensitizing adipocyte-derived protein. Diabetes 2002, 51: 2734-2741. 10.2337/diabetes.51.9.2734CrossRefPubMed

Saito K, Tobe T, Minoshima S, Asakawa S, Sumiya J, Yoda M, Nakano Y, Shimizu N, Tomita M: Organization of the gene for gelatin-binding protein (GBP28). Gene 1999, 229: 67-73. 10.1016/S0378-1119(99)00041-4CrossRefPubMed

10.

Simpson F, Whitehead JP: Adiponectin - it's all about the modifications. Int J Biochem Cell Biol 42: 785-788. 10.1016/j.biocel.2009.12.021

11.

Liu M, Liu F: Transcriptional and post-translational regulation of adiponectin. Biochem J 2009, 425: 41-52. 10.1042/BJ20091045CrossRefPubMed

12.

Halberg N, Schraw TD, Wang ZV, Kim J-Y, Yi J, Hamilton MP, Luby-Phelps K, Scherer PE: Systemic fate of the adipocyte-derived factor adiponectin. Diabetes 2009, 58: 1961-1970. 10.2337/db08-1750PubMedCentralCrossRefPubMed

13.

Komura N, Kihara S, Sonoda M, Maeda N, Tochino Y, Funahashi T, Shimomura I: Increment and impairment of adiponectin in renal failure. Cardiovasc Res 2010, 86: 471-477. 10.1093/cvr/cvp415CrossRefPubMed

14.

Shen YY, Charlesworth JA, Kelly JJ, Peake PW: The effect of renal transplantation on adiponectin and its isoforms and receptors. Metabolism 2007, 56: 1201-1208. 10.1016/j.metabol.2007.04.016CrossRefPubMed

15.

Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423: 762-769. 10.1038/nature01705CrossRefPubMed

16.

Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K, Kozono H, Hada Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Awazawa M, Takamoto I, Froguel P, Hara K, Tobe K, Nagai R, Ueki K, Kadowaki T: Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007, 13: 332-339. 10.1038/nm1557CrossRefPubMed

17.

Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF: T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 2004, 101: 10308-10313. 10.1073/pnas.0403382101PubMedCentralCrossRefPubMed

18.

Yoon MJ, Lee GY, Chung J-J, Ahn YH, Hong SH, Kim JB: Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes 2006, 55: 2562-2570. 10.2337/db05-1322CrossRefPubMed

19.

Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8: 1288-1295. 10.1038/nm788CrossRefPubMed

20.

Joshi MB, Philippova M, Ivanov D, Allenspach R, Erne P, Resink TJ: T-cadherin protects endothelial cells from oxidative stress-induced apoptosis. FASEB J 2005, 19: 1737-1739.PubMed

21.

Takeuchi T, Adachi Y, Ohtsuki Y, Furihata M: Adiponectin receptors, with special focus on the role of the third receptor, T-cadherin, in vascular disease. Med Mol Morphol 2007, 40: 115-120. 10.1007/s00795-007-0364-9CrossRefPubMed

22.

Ziemke F, Mantzoros CS: Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr 2010, 91: 258S-261S. 10.3945/ajcn.2009.28449CPubMedCentralCrossRefPubMed

23.

Hu E, Liang P, Spiegelman BM: AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996, 271: 10697-10703. 10.1074/jbc.271.18.10697CrossRefPubMed

24.

Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y: Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8: 731-737. 10.1038/nm724CrossRefPubMed

25.

Han SH, Sakuma I, Shin EK, Koh KK: Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. Prog Cardiovasc Dis 52: 126-140. 10.1016/j.pcad.2009.06.004

26.

Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, Imai Y, Nagai R, Kadowaki T: Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006, 29: 1357-1362. 10.2337/dc05-1801CrossRefPubMed

27.

Hung J, McQuillan BM, Thompson PL, Beilby JP: Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity. Int J Obes (Lond) 2008, 32: 772-779. 10.1038/sj.ijo.0803793CrossRef

28.

Kaser S, Tatarczyk T, Stadlmayr A, Ciardi C, Ress C, Tschoner A, Sandhofer A, Paulweber B, Ebenbichler CF, Patsch JR: Effect of obesity and insulin sensitivity on adiponectin isoform distribution. Eur J Clin Invest 2008, 38: 827-834. 10.1111/j.1365-2362.2008.02028.xCrossRefPubMed

29.

Rovin BH, Song H, Hebert LA, Nadasdy T, Nadasdy G, Birmingham DJ, Yung Yu C, Nagaraja HN: Plasma, urine, and renal expression of adiponectin in human systemic lupus erythematosus. Kidney Int 2005, 68: 1825-1833. 10.1111/j.1523-1755.2005.00601.xCrossRefPubMed

30.

Moriconi N, Kraenzlin M, Muller B, Keller U, Nusbaumer CP, Stohr S, Tamm M, Puder JJ: Body composition and adiponectin serum concentrations in adult patients with cystic fibrosis. J Clin Endocrinol Metab 2006, 91: 1586-1590. 10.1210/jc.2005-2135CrossRefPubMed

31.

Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA: Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis 2006, 12: 100-105. 10.1097/01.MIB.0000200345.38837.46CrossRefPubMed

32.

Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gomez-Reino JJ, Gualillo O: Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65: 1198-1201. 10.1136/ard.2005.046540PubMedCentralCrossRefPubMed

33.

Pang TTL, Narendran P: The distribution of adiponectin receptors on human peripheral blood mononuclear cells. Ann N Y Acad Sci 2008, 1150: 143-145. 10.1196/annals.1447.021CrossRefPubMed

34.

Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y: Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000, 96: 1723-1732.PubMed

35.

Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y: Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103: 1057-1063.CrossRefPubMed

36.

Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K, Maeda K, Nagaretani H, Kishida K, Maeda N, Nagasawa A, Funahashi T, Matsuzawa Y: Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004, 109: 2046-2049. 10.1161/01.CIR.0000127953.98131.EDCrossRefPubMed

37.

Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100: 2473-2476.CrossRefPubMed

38.

Yamaguchi N, Argueta JG, Masuhiro Y, Kagishita M, Nonaka K, Saito T, Hanazawa S, Yamashita Y: Adiponectin inhibits Toll-like receptor familyinduced signaling. FEBS Lett 2005, 579: 6821-6826. 10.1016/j.febslet.2005.11.019CrossRefPubMed

39.

Magalang UJ, Rajappan R, Hunter MG, Kutala VK, Kuppusamy P, Wewers MD, Marsh CB, Parinandi NL: Adiponectin inhibits superoxide generation by human neutrophils. Antioxid Redox Signal 2006, 8: 2179-2186. 10.1089/ars.2006.8.2179CrossRefPubMed

40.

Waki H, Yamauchi T, Kamon J, Kita S, Ito Y, Hada Y, Uchida S, Tsuchida A, Takekawa S, Kadowaki T: Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology 2005, 146: 790-796. 10.1210/en.2004-1096CrossRefPubMed

41.

Tsao T-S, Murrey HE, Hug C, Lee DH, Lodish HF: Oligomerization statedependent activation of NF-kB signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem 2002, 277: 29359-29362. 10.1074/jbc.C200312200CrossRefPubMed

42.

Tomizawa A, Hattori Y, Kasai K: Induction of gene expression in response to globular adiponectin in vascular endothelial cells. Life Sci 2009, 85: 457-461. 10.1016/j.lfs.2009.07.012CrossRefPubMed

43.

Tang C-H, Chiu Y-C, Tan T-W, Yang R-S, Fu W-M: Adiponectin enhances IL-6 production in human synovial fibroblast via an AdipoR1 receptor, AMPK, p38, and NF-{kappa}B pathway. J Immunol 2007, 179: 5483-5492.CrossRefPubMed

44.

Wanninger J, Neumeier M, Weigert J, Bauer S, Weiss TS, Schäffler A, Krempl C, Bleyl C, Aslanidis C, Schölmerich J, Buechler C: Adiponectin-stimulated CXCL8 release in primary human hepatocytes is regulated by ERK1/ERK2, p38 MAPK, NF-{kappa}B, and STAT3 signaling pathways. Am J Physiol Gastrointest Liver Physiol 2009, 297: G611-618. 10.1152/ajpgi.90644.2008CrossRefPubMed

45.

Ajuwon KM, Spurlock ME: Adiponectin inhibits LPS-induced NF-{kappa}B activation and IL-6 production and increases PPAR{gamma}2 expression in adipocytes. Am J Physiol Regul Integr Comp Physiol 2005, 288: R1220-1225. 10.1152/ajpregu.00397.2004CrossRefPubMed

46.

Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000, 102: 1296-1301.CrossRefPubMed

47.

Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME: Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 2004, 316: 924-929. 10.1016/j.bbrc.2004.02.130CrossRefPubMed

48.

Kim KY, Kim JK, Han SH, Lim JS, Kim KI, Cho DH, Lee MS, Lee JH, Yoon DY, Yoon SR, Chung JW, Choi I, Kim E, Yang Y: Adiponectin is a negative regulator of NK cell cytotoxicity. J Immunol 2006, 176: 5958-5964.CrossRefPubMed

49.

Hattori Y, Nakano Y, Hattori S, Tomizawa A, Inukai K, Kasai K: High molecular weight adiponectin activates AMPK and suppresses cytokine-induced NF-kappaB activation in vascular endothelial cells. FEBS Lett 2008, 582: 1719-1724. 10.1016/j.febslet.2008.04.037CrossRefPubMed

50.

Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A, Richelsen B: Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003, 285: E527-533.CrossRefPubMed

51.

Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G: Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003, 52: 1779-1785. 10.2337/diabetes.52.7.1779CrossRefPubMed

52.

Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y: PPARgamma ligands increaseexpression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001, 50: 2094-2099. 10.2337/diabetes.50.9.2094CrossRefPubMed

53.

Kappes A, Loffler G: Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm Metab Res 2000, 32: 548-554. 10.1055/s-2007-978684CrossRefPubMed

54.

Keller P, Moller K, Krabbe KS, Pedersen BK: Circulating adiponectin levels during human endotoxaemia. Clin Exp Immunol 2003, 134: 107-110. 10.1046/j.1365-2249.2003.02264.xPubMedCentralCrossRefPubMed

55.

Anderson PD, Mehta NN, Wolfe ML, Hinkle CC, Pruscino L, Comiskey LL, Tabita-Martinez J, Sellers KF, Rickels MR, Ahima RS, Reilly MP: Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab 2007, 92: 2272-2279. 10.1210/jc.2006-2545CrossRefPubMed

56.

Uji Y, Yamamoto H, Tsuchihashi H, Maeda K, Funahashi T, Shimomura I, Shimizu T, Endo Y, Tani T: Adiponectin deficiency is associated with severe polymicrobial sepsis, high inflammatory cytokine levels, and high mortality. Surgery 2009, 145: 550-557. 10.1016/j.surg.2009.01.010CrossRefPubMed

57.

Uji Y, Yamamoto H, Maeda K, Tsuchihashi H, Akabori H, Shimizu T, Endo Y, Shimomura I, Tani T: Adiponectin deficiency promotes the production of inflammatory mediators while severely exacerbating hepatic injury in mice with polymicrobial sepsis. J Surg Res 2010, 161: 301-311. 10.1016/j.jss.2008.12.021CrossRefPubMed

58.

Hillenbrand A, Knippschild U, Weiss M, Schrezenmeier H, Henne-Bruns D, Huber-Lang M, Wolf AM: Sepsis induced changes of adipokines and cytokines - septic patients compared to morbidly obese patients. BMC Surg 2010, 10: 26. 10.1186/1471-2482-10-26PubMedCentralCrossRefPubMed

59.

Tsuchihashi H, Yamamoto H, Maeda K, Ugi S, Mori T, Shimizu T, Endo Y, Hanasawa K, Tani T: Circulating concentrations of adiponectin, an endogenous lipopolysaccharide neutralizing protein, decrease in rats with polymicrobial sepsis. J Surg Res 2006, 134: 348-353. 10.1016/j.jss.2006.01.001CrossRefPubMed

60.

Teoh H, Quan A, Bang KW, Wang G, Lovren F, Vu V, Haitsma JJ, Szmitko PE, Al-Omran M, Wang CH, Gupta M, Peterson MD, Zhang H, Chan L, Freedman J, Sweeney G, Verma S: Adiponectin deficiency promotes endothelial activation and profoundly exacerbates sepsis-related mortality. Am J Physiol Endocrinol Metab 2008, 295: E658-664. 10.1152/ajpendo.90384.2008PubMedCentralCrossRefPubMed

61.

Pini M, Sennello JA, Chan L, Fantuzzi G: Adiponectin deficiency does not affect the inflammatory response to endotoxin or concanavalin a in mice. Endocrinology 2006, 147: 5019-5022. 10.1210/en.2006-0855CrossRefPubMed

62.

Pini M, Gove ME, Sennello JA, van Baal JW, Chan L, Fantuzzi G: Role and regulation of adipokines during zymosan-induced peritoneal inflammation in mice. Endocrinology 2008, 149: 4080-4085. 10.1210/en.2008-0327PubMedCentralCrossRefPubMed

63.

Jernas M, Olsson B, Sjoholm K, Sjogren A, Rudemo M, Nellgard B, Carlsson LM, Sjostrom CD: Changes in adipose tissue gene expression and plasma levels of adipokines and acute-phase proteins in patients with critical illness. Metabolism 2009, 58: 102-108. 10.1016/j.metabol.2008.08.012CrossRefPubMed

64.

Venkatesh B, Hickman I, Nisbet J, Cohen J, Prins J: Changes in serum adiponectin concentrations in critical illness: a preliminary investigation. Crit Care 2009, 13: R105. 10.1186/cc7941PubMedCentralCrossRefPubMed

65.

Langouche L, Vander Perre S, Frystyk J, Flyvbjerg A, Hansen TK, Van den Berghe G: Adiponectin, retinol-binding protein 4, and leptin in protracted critical illness of pulmonary origin. Crit Care 2009, 13: R112. 10.1186/cc7956PubMedCentralCrossRefPubMed

66.

Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y: Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003, 107: 671-674. 10.1161/01.CIR.0000055188.83694.B3CrossRefPubMed

67.

Engeli S, Feldpausch M, Gorzelniak K, Hartwig F, Heintze U, Janke J, Mohlig M, Pfeiffer AF, Luft FC, Sharma AM: Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003, 52: 942-947. 10.2337/diabetes.52.4.942CrossRefPubMed

68.

Walkey AJ, Rice TW, Konter J, Ouchi N, Shibata R, Walsh K, deBoisblanc BP, Summer R: Plasma adiponectin and mortality in critically ill subjects with acute respiratory failure. Crit Care Med 2010, 38: 2329-2334. 10.1097/CCM.0b013e3181fa0561PubMedCentralCrossRefPubMed

69.

Kaplan JM, Denenberg A, Monaco M, Nowell M, Wong H, Zingarelli B: Changes in peroxisome proliferator-activated receptor-gamma activity in children with septic shock. Intensive Care Med 2010, 36: 123-130. 10.1007/s00134-009-1654-6PubMedCentralCrossRefPubMed

70.

Ouedraogo R, Gong Y, Berzins B, Wu X, Mahadev K, Hough K, Chan L, Goldstein BJ, Scalia R: Adiponectin deficiency increases leukocyteendothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest 2007, 117: 1718-1726. 10.1172/JCI29623PubMedCentralCrossRefPubMed

71.

Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H, Kumada M, Ohashi K, Okamoto Y, Nishizawa H, Kishida K, Maeda N, Nagasawa A, Kobayashi H, Hiraoka H, Komai N, Kaibe M, Rakugi H, Ogihara T, Matsuzawa Y: Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003, 42: 231-234. 10.1161/01.HYP.0000083488.67550.B8CrossRefPubMed

72.

Palmer C, Hampartzoumian T, Lloyd A, Zekry A: A novel role for adiponectin in regulating the immune responses in chronic hepatitis C virus infection. Hepatology 2008, 48: 374-384. 10.1002/hep.22387CrossRefPubMed

73.

Shetty S, Kusminski CM, Scherer PE: Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci 2009, 30: 234-239. 10.1016/j.tips.2009.02.004CrossRefPubMed

74.

Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995, 270: 12953-12956. 10.1074/jbc.270.50.30221CrossRefPubMed

75.

Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988, 37: 1549-1558. 10.2337/diabetes.37.11.1549CrossRefPubMed

76.

Qurashi S, Mynarcik DC, McNurlan MA, Ahn H, Ferris R, Gelato MC: Importance of the high-molecular-mass isoform of adiponectin in improved insulin sensitivity with rosiglitazone treatment in HIV disease. Clin Sci (Lond) 2008, 115: 197-202. 10.1042/CS20070387CrossRef

77.

Phillips SA, Kung J, Ciaraldi TP, Choe C, Christiansen L, Mudaliar S, Henry RR: Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans. Am J Physiol Endocrinol Metab 2009, 297: E767-773. 10.1152/ajpendo.00378.2009PubMedCentralCrossRefPubMed

78.

Oki K, Koide J, Nakanishi S, Nakashima R, Yamane K: Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia. Endocr J 2007, 54: 431-435. 10.1507/endocrj.K06-172CrossRefPubMed

79.

Westphal S, Luley C: Preferential increase in high-molecular weight adiponectin after niacin. Atherosclerosis 2008, 198: 179-183. 10.1016/j.atherosclerosis.2007.09.036CrossRefPubMed

80.

Leuwer M, Welters I, Marx G, Rushton A, Bao H, Hunter L, Trayhurn P: Endotoxaemia leads to major increases in inflammatory adipokine gene expression in white adipose tissue of mice. Pflugers Arch 2009, 457: 731-741. 10.1007/s00424-008-0564-8CrossRefPubMed

Title: Clinical review: Adiponectin biology and its role in inflammation and critical illness
Authors: Katherine Robinson
John Prins
Bala Venkatesh
Publication date: 01-04-2011
Publisher: BioMed Central
Published in: Critical Care / Issue 2/2011
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/cc10021

At a glance: The STEP trials

Springer Medicine

Clinical review: Adiponectin biology and its role in inflammation and critical illness

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

European legislation impedes critical care research and fails to protect patients' rights

Respiratory pulse pressure variation fails to predict fluid responsiveness in acute respiratory distress syndrome

Greening critical care

Genetic variation of TLR4 influences immunoendocrine stress response: an observational study in cardiac surgical patients

Access block and emergency department overcrowding

Extracorporeal cell therapy of septic shock patients with donor granulocytes: a pilot study